These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A novel orally active dopamine prodrug TA-870. II. Evidence that TA-870 is a dopamine prodrug.
    Author: Nishiyama S, Yamaguchi I, Akimoto Y, Yoshikawa M, Nakajima H.
    Journal: J Cardiovasc Pharmacol; 1989 Aug; 14(2):175-83. PubMed ID: 2476589.
    Abstract:
    The mechanism of action of a new orally active dopamine (DA) prodrug, TA-870 (N-(N-acetyl-L-methionyl)-O,O-bis(ethoxycarbonyl)(DA) was studied. When TA-870 (1 mg/kg) was injected in anesthetized dogs, renal vascular resistance was decreased and renal blood flow was increased. The renal vasodilatory effect of TA-870 correlated with the plasma level of DA but not with the level of de-ethoxycarbonyl metabolite of TA-870 (i.e., N-(N-acetyl-L-methionyl)DA; DEC-TA-870). The renal vasodilatory effect of TA-870 was inhibited strongly by haloperidol and slightly by propranolol. Pretreatment with phenoxybenzamine enhanced the renal vasodilatory effect of TA-870. In the isolated rabbit splenic artery, TA-870 and DEC-TA-870 showed no effects, whereas dopamine showed a contracting effect, which was inhibited by phentolamine. In the propranolol- and phentolamine-treated splenic artery, TA-870 and DEC-TA-870 caused weak relaxant effects on PGF2 alpha-induced contraction. These effects were not antagonized by metoclopramide. On the other hand, DA showed a strong relaxant effect, which was competitively inhibited by metoclopramide. In addition, TA-870 and DEC-TA-870 further relaxed the artery that had been maximally relaxed by DA. We concluded that TA-870 and DEC-TA-870 exert weak vasodilatory effects that are different from that of DA in vitro, and that TA-870 exerts its vasodilatory effect after its conversion to free DA in vivo.
    [Abstract] [Full Text] [Related] [New Search]